Conference Track

Investigational Antiretrovirals

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Capsule Summaries

VICTOR-E1: Vicriviroc Plus OBR Generally Well Tolerated in Treatment-Experienced Patients at 24 Weeks
Case Reports Suggest Cross-Resistance May Limit Ability to Administer Integrase Inhibitors Sequentially
Novel NNRTI Rilpivirine (TMC278) May Be Associated With Fewer CNS and Psychiatric Adverse Events Than Efavirenz
Novel CCR5 Inhibitor INCB009471 Safe and Potent in HIV-Infected Patients in 14-Day Monotherapy Study
Raltegravir Demonstrates Rapid and Sustained Antiretroviral Efficacy in Treatment-Naive HIV-Infected Patients: 48-Week Results
Rilpivirine Associated With Smaller Changes in Metabolic Parameters Than Efavirenz After 48 Weeks in Treatment-Naive Patients
Raltegravir Produces Different HIV Viral Decay Kinetics Than Traditional Antiretrovirals; Supports Potency of Raltegravir and Challenges Current Hypotheses of Viral Replication
Pooled Data From MOTIVATE 1 and 2 Confirm Increased Efficacy of Maraviroc When Combined With at Least 1 Active Agent in OBR
Pooled Analysis of MOTIVATE 1 and 2 Confirms Efficacy, Supports Proposed Twice-Daily Administration
PRO 140, a Novel CCR5 Inhibitor, Both Safe and Highly Potent in Asymptomatic, HIV-Infected Individuals
DUET-1 and -2: Etravirine (TMC125) Plus Darunavir/Ritonavir-Based Regimen Associated With High Rates of Viral Suppression in Treatment-Experienced HIV-Infected Patients
7-Day UK-453,061 Monotherapy Safe and Effective in HIV-Infected Men
Vicriviroc, a CCR5 Antagonist, Effective in Treatment-Experienced Patients: 48-Week Results
Maraviroc Fails to Meet Rigorous Noninferiority Criteria Compared With Efavirenz in First-Line Therapy

Expert Analysis

Investigational Antiretrovirals

Faculty:
Pedro Cahn, MD, PhD Joseph J. Eron, Jr., MD Daniel R. Kuritzkes, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify investigational antiretrovirals in early or late stages of clinical development
Summarize the results of recent clinical studies involving investigational antiretrovirals
Specify which investigational agents have been studied in treatment-naive vs treatment-experienced patients

CME CREDIT INFORMATION

Release Date: 09/14/07

Expiration Date: 09/13/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.2 contact hours (0.12 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.